Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Watson Oxytrol Approval Expected In 2003; Patch Is “Not Approvable” At FDA

Executive Summary

Watson Pharmaceuticals expects the overactive bladder patch Oxytrol to be cleared by FDA in the first quarter of 2003, following receipt of a "not approvable" letter March 26

You may also be interested in...



Somerset Emsam Safety Data Should Be Collected To Remove Restrictions

Somerset should amass safety data on its Emsam (selegiline) patches that would allow FDA to remove dietary restrictions on all strengths of the major depression therapy, the Psychopharmacologic Drugs Advisory Committee said Oct. 26

Somerset Emsam Safety Data Should Be Collected To Remove Restrictions

Somerset should amass safety data on its Emsam (selegiline) patches that would allow FDA to remove dietary restrictions on all strengths of the major depression therapy, the Psychopharmacologic Drugs Advisory Committee said Oct. 26

Watson Oxytrol Dry Mouth Profile Gives Overactive Bladder Patch Marketing Edge

Watson's Oxytrol dry mouth side effect profile gives the overactive bladder patch a marketing edge over oral anticholinergic agents

Related Content

UsernamePublicRestriction

Register

PS039596

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel